{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:36:00Z","timestamp":1760121360136,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1016\/j.revmed.2005.09.020","type":"journal-article","created":{"date-parts":[[2005,11,9]],"date-time":"2005-11-09T07:15:49Z","timestamp":1131520549000},"page":"400-405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pentoxifylline\u00a0: l'anti-TNF du\u00a0pauvre\u00a0?"],"prefix":"10.1016","volume":"27","author":[{"given":"M.","family":"Koenig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Cath\u00e9bras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Guy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Rousset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2005.09.020_bib1","first-page":"765","article-title":"Management of intermittent claudication with pentoxifylline\u00a0: meta-analysis of randomized controlled trials","volume":"156","author":"Hood","year":"1997","journal-title":"CMAJ"},{"key":"10.1016\/j.revmed.2005.09.020_bib2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archinte.159.4.337","article-title":"Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis","volume":"159","author":"Girolami","year":"1999","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.revmed.2005.09.020_bib3","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2165\/00003495-200059050-00003","article-title":"Pharmacological management of intermittent claudication: a meta-analysis of randomized trials","volume":"59","author":"Moher","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.revmed.2005.09.020_bib4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2165\/00003495-198734010-00003","article-title":"Pentoxyfilline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy","volume":"34","author":"Ward","year":"1987","journal-title":"Drugs"},{"key":"10.1016\/j.revmed.2005.09.020_bib5","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJM200108023450506","article-title":"Autoimmune diseases","volume":"345","author":"Davidson","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.revmed.2005.09.020_bib6","first-page":"595","article-title":"Phosphodiesterase inhibitor pentoxifylline: an antiinflammatory immunomodulatory drug potentially useful in some rheumatic diseases","volume":"22","author":"Anaya","year":"1995","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.revmed.2005.09.020_bib7","first-page":"625","article-title":"An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis","volume":"22","author":"Maksymowych","year":"1995","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.revmed.2005.09.020_bib8","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/rheumatology\/37.9.1033","article-title":"An open study of oxpentifylline in early rheumatoid arthritis","volume":"37","author":"Kiely","year":"1998","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.revmed.2005.09.020_bib9","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1136\/ard.55.11.833","article-title":"An open study of pentoxifylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis","volume":"55","author":"Huizinga","year":"1996","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.revmed.2005.09.020_bib10","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1097\/01.ASN.0000140218.77174.0A","article-title":"Management of lupus nephritis: an update","volume":"15","author":"Houssiau","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.revmed.2005.09.020_bib11","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2337\/diacare.22.6.1006","article-title":"Antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy","volume":"22","author":"Navarro","year":"1999","journal-title":"Diab. Care"},{"key":"10.1016\/j.revmed.2005.09.020_bib12","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S0140-6736(00)04830-3","article-title":"Use of pentoxifylline in membranous nephropathy","volume":"357","author":"Ducloux","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2005.09.020_bib13","first-page":"2382","article-title":"Pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis","volume":"30","author":"Galindo-Rodriguez","year":"2003","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.revmed.2005.09.020_bib14","doi-asserted-by":"crossref","first-page":"891","DOI":"10.7326\/0003-4819-124-10-199605150-00005","article-title":"Successful treatment of Beh\u00e7et disease with pentoxifylline","volume":"124","author":"Yasui","year":"1996","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.revmed.2005.09.020_bib15","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/0-306-48382-3_120","article-title":"Pentoxifylline use for Beh\u00e7et's disease","volume":"528","author":"Liang","year":"2003","journal-title":"Adv. Exp. Biol. Med."},{"key":"10.1016\/j.revmed.2005.09.020_bib16","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1365-2133.1995.tb02728.x","article-title":"Treatment of recurrent aphthous stomatitis with pentoxifylline","volume":"133","author":"Pizzaro","year":"1995","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.revmed.2005.09.020_bib17","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/0190-9622(95)91310-6","article-title":"Pentoxifylline in intractable recurrent aphthous stomatitis\u00a0: an open trial","volume":"33","author":"Wahba-Yahav","year":"1995","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.revmed.2005.09.020_bib18","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(94)92746-4","article-title":"Synergistic effects of pentoxifylline and dapsone in leucocytoclasic vasculitis","volume":"343","author":"N\u00fcrnberg","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2005.09.020_bib19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2340\/00015555755456","article-title":"Urticarial vasculitis syndrome effectively treated with dapsone and pentoxifylline","volume":"75","author":"N\u00fcrnberg","year":"1995","journal-title":"Acta Dermatol. Venereol."},{"key":"10.1016\/j.revmed.2005.09.020_bib20","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/BF02190688","article-title":"Pentoxifylline and intravenous gammaglobulin combination therapy for acute Kawasaki disease","volume":"153","author":"Furukawa","year":"1994","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.revmed.2005.09.020_bib21","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1365-2133.1993.tb00276.x","article-title":"Successful treatment of cutaneous PAN with pentoxifylline","volume":"128","author":"Calderon","year":"1993","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.revmed.2005.09.020_bib22","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0140-6736(03)12888-7","article-title":"Sarcoidosis","volume":"361","author":"Baughmann","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2005.09.020_bib23","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1164\/ajrccm.159.2.9804085","article-title":"Pentoxifylline inhibits TNF-alpha production from alveolar human macrophages","volume":"159","author":"Marques","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.revmed.2005.09.020_bib24","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1164\/ajrccm.155.5.9154873","article-title":"Pentoxifylline in treatment of sarcoidosis","volume":"155","author":"Zabel","year":"1997","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.revmed.2005.09.020_bib25","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/gut.40.4.475","article-title":"In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease","volume":"40","author":"Reimund","year":"1997","journal-title":"Gut"},{"key":"10.1016\/j.revmed.2005.09.020_bib26","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/gut.40.4.470","article-title":"Treatment with Tumor Necrosis Factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease","volume":"40","author":"Bauditz","year":"1997","journal-title":"Gut"},{"key":"10.1016\/j.revmed.2005.09.020_bib27","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1053\/gast.2000.20189","article-title":"Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial","volume":"119","author":"Akriviadis","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2005.09.020_bib28","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1111\/j.1572-0241.2004.40220.x","article-title":"Beneficial effects of Tumor Necrosis Factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis","volume":"99","author":"Satapathy","year":"2004","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.revmed.2005.09.020_bib29","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1111\/j.1572-0241.2004.40064.x","article-title":"A pilot trial of pentoxifylline in nonalcoholic steatohepatitis","volume":"99","author":"Adams","year":"2004","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.revmed.2005.09.020_bib30","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(02)08513-6","article-title":"Pentoxifylline for treatment of venous leg ulcers: a systematic review","volume":"359","author":"Jull","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2005.09.020_bib31","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V95.5.1580.005k45_1580_1587","article-title":"Patients with myelodysplastic syndromes benefit from palliative theapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone","volume":"95","author":"Raza","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2005.09.020_bib32","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/archsurg.133.1.94","article-title":"Effect of pentoxifylline in severe sepsis","volume":"133","author":"Staubach","year":"1998","journal-title":"Arch. Surg."},{"key":"10.1016\/j.revmed.2005.09.020_bib33","series-title":"Meyler's side effects of drugs, 14e ed","first-page":"629","article-title":"Drugs acting on the cerebral and peripheral circulations and drugs used in the treatment of migraine","author":"Verhaeghe","year":"2000"},{"key":"10.1016\/j.revmed.2005.09.020_bib34","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1212\/01.WNL.0000032107.87017.DA","article-title":"Pentoxifylline-induced aseptic meningitidis in a patient with mixed connective tissue disease","volume":"59","author":"Mathian","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.revmed.2005.09.020_bib35","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1440-1797.2004.00267.x","article-title":"Pentoxifylline: a potential therapy for chronic kidney disease","volume":"9","author":"Lin","year":"2004","journal-title":"Nephrol."}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866305004261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866305004261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:19:25Z","timestamp":1759335565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866305004261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S0248866305004261"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2005.09.020","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2006,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pentoxifylline\u00a0: l'anti-TNF du\u00a0pauvre\u00a0?","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2005.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}